77 more hepatitis cases may trace to clinic, officials say
LAS VEGAS -- Seventy-seven more people that were treated at a Las Vegas outpatient clinic have been diagnosed with hepatitis C, health officials said. Authorities can't say for sure how the 77 people were infected, said Brian Labus, senior epidemiologist
77 more hepatitis cases may trace to clinic at center of Las Vegas outbreak, officials say
AM LAS VEGAS-Seventy-seven more people that were treated at a Las Vegas outpatient clinic accused of reusing syringes on thousands of people have been diagnosed with Hepatitis C, health officials said. Authorities cannot say for sure how the 77 people
77 more hepatitis cases may trace to clinic, officials say
Seventy-seven more people that were treated at a Las Vegas outpatient clinic have been diagnosed with hepatitis C, health officials said.Authorities can't say for sure how the 77 people were infected, said Brian Labus, senior epidemiologist with the
|
|
|
Highly Effective Against HCV Genotype 1
When tested on people with Hepatitis C genotype 1, R7128 proved to be an effective addition to combination therapy after just four weeks' time. In addition to its anti-viral effect, polymerase inhibitor R7128 received good marks for safety and minimal...
Investigational Drug Beats Standard Therapy in Hepatitis C Study
A Phase IIa trial investigating triple combination therapy with PEGASYS, COPEGUS and Roche's investigational drug R1626, demonstrated a higher response rate than traditional combination therapy alone. While R1626's effectiveness and high barrier to resistance makes it a top Hepatitis C...
Hepatitis C Complications Helped by Maintenance Interferon
A four-year study confirms that low-dosage maintenance interferon therapy prevents disease progression in those with portal hypertension or cirrhosis from Hepatitis C....
|
|
|
Dig Dis Sci 1997 Aug;42(8):1681-1687
Treatment of chronic Hepatitis C with amantadine.
Smith JP
Department of Medicine, Milton S. Hershey Medical Center, Pennsylvania State University,
Hershey 17033, USA.
Treatment of chronic Hepatitis C infection with interferon has been disappointing,
with less than one third of patients achieving a sustained response and most experiencing
significant side effects. For these reasons, an open-labeled prospective pilot
study was conducted to test the safety and efficacy of the antiviral drug, amantadine,
in patients with chronic Hepatitis C infection who had previously failed therapy
with interferon-alpha 2b. Twenty-two patients with chronic Hepatitis C were enrolled
into the study and treated with amantadine 100 mg orally twice daily for six months.
Control groups included the same cohort followed off therapy for 29-36 months
or during therapy with interferon. Serum alanine aminotransferase (ALT) values
decreased in 64% (P = 0.01) of patients with amantadine therapy compared to intervals
without therapy or to interferon therapy. Twenty-seven percent of patients treated
with amantadine had normalization of ALT values and loss of HCV RNA after six
months while 18% achieved a sustained response with loss of HCV RNA by PCR six
months after discontinuation of amantadine. Therapy with amantadine improved both
biochemical and virological markers in patients with Hepatitis C who had previously
not responded to treatment with interferon.
PMID: 9286234, UI: 97432335
|
|
